Axonics reports Q3 EPS 0c, consensus 13c
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Should l Buy ?
Q3 Revenue Performance: Axonics reported Q3 revenue of $116.2 million, exceeding the consensus estimate of $113.5 million, marking a 25% year-over-year growth.
Growth Drivers: The revenue increase was attributed to higher utilization from existing customers and the onboarding of new accounts for both sacral neuromodulation and Bulkamid(R).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
